Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)

April 2021

You’ll hear concerns about using an injectable CGRP antagonist (Aimovig, etc) for migraine prophylaxis in patients with CV risks.

Most data suggest that CGRP antagonists have minimal CV impact. But it’s mostly short-term data in young patients without CV risks.

Now an FDA review suggests new-onset or worsening hypertension with Aimovig (erenumab)...prompting labeling updates.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote